Their mission is to capture and analyze genetic and epigenetic information simultaneously, providing valuable insights into normal and disease biology. Current technologies often fail to capture both genetic and epigenetic sequences, leading to a loss of important information. However, biomodal revolutionizes this process by enabling users to measure multiple modalities in a single workflow, with an astonishingly low DNA input requirement of just 10ng.

With biomodal, researchers can delve into the complexities of biology, combining epigenetic and genetic analysis within a single sequencing run. This powerful approach allows for a deeper understanding of critical information derived from DNA samples, particularly in fields such as cancer research, aging, population genetics, non-invasive prenatal testing, neurodegenerative diseases, and precision medicine. Additionally, biomodal introduces the innovative duet multiomics solution, +modC, which consolidates multiple workflows into one, providing access to both genetic and epigenetic sequence data from a single sample.

At biomodal, a culture of curiosity and exploration thrives. Their talented team continues to push the boundaries of innovation in the field of epigenetics, attracting professionals like Chad Geringer and Dr. Aziz Mustafa, who bring expertise and passion to the business development and sales departments.

To stay informed about the latest developments and breakthroughs in the field, biomodal offers a comprehensive product portal and encourages researchers and scientists to get in touch. With a strong commitment to science and a dedication to advancing knowledge, biomodal is shaping the future of biology exploration